Course Videos
Based on the results of the LEADER trial, where would you likely position liraglutide in the framework of individualized ADA/EASD guidelines?
Can you describe the kinds of patients evaluated in the LEADER trial and, based on the results, what CV risk groups and clinical profiles with T2D would be most amenable to treatment with liraglutide?
What aspects of the overall design and implementation of the LEADER trial do you think deserve the greatest emphasis? What metabolic target goals and CV outcomes achieved by liraglutide do you think were most significant?
Based on LEADER, what do you believe the implications are for the use of liraglutide to mitigate or stabilize diabetic nephropathy? What degree of CV event reduction was observed in patients with CKD?
What outcomes was the LEADER trial powered to assess? Can you specifically discuss the secondary microvascular outcomes in the kidney?
Do you have any explanation for why liraglutide was associated a lower risk of hypoglycemia than in the control arm of the LEADER trial?
Based on the results of the LEADER trial, where would you position liraglutide in the ADA/EASD sequencing algorithm for antidiabetic agents?
How do you interpret the LEADER results showing reduction in microvascular events as well as macrovascular events. What drove these reductions?
Based on LEADER, is there an ideal age group for liraglutide? Should it be used in younger and older patients? What dose should we be trying to achieve? What is the toleration profile?
Which patient subgroups, based on the LEADER trial, are most likely to benefit from liraglutide therapy? High risk? Low risk? Both? At what point in the natural history of T2D? Early? Late? Both?
Which results from the LEADER trial do you consider to be most transformative as far as our approach to CV risk reduction in T2D, and what might the implications be about the mechanism by which liraglutide reduces CV events?
What are the clinical implications of the fact that liraglutide’s benefits were seen in a high risk population that was already on maximal therapy for CV risk reduction?